CCL5 (6A1) Monoclonal Antibody

$Lane 1: Mouse Thymus; Probed with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Mouse Thymus; Probed with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in HUVEC cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in HUVEC cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Breast Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Breast Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse

Overview
Catalog #	bsm-54125R
Product Name	CCL5 (6A1) Monoclonal Antibody
Applications	WB, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein.
Clonality	Monoclonal
Clone #	6A1
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6352
Swiss Prot	P13501
Subcellular location	Secreted
Synonyms	C-C motif chemokine 5; EoCP; Eosinophil chemotactic cytokine; SIS-delta; Small-inducible cytokine A5; T cell-specific protein P228; T-cell-specific protein RANTES; TCP228; CCL5; D17S136E; SCYA5.
Background	Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils. May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200